316 related articles for article (PubMed ID: 11995445)
21. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
22. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.
Foon KA; Sen G; Hutchins L; Kashala OL; Baral R; Banerjee M; Chakraborty M; Garrison J; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1998 May; 4(5):1117-24. PubMed ID: 9607568
[TBL] [Abstract][Full Text] [Related]
23. Cytokine-based therapy for melanoma: pre-clinical studies.
Shurin MR; Kirkwood JM; Esche C
Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
[TBL] [Abstract][Full Text] [Related]
24. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.
Mantovani G; Macciò A; Madeddu C; Mulas C; Massa E; Astara G; Ferreli L; Mudu MC; Gramignano G; Murgia V; Lusso MR; Mocci M; Cardia A; Mura L
Oncol Rep; 2002; 9(4):887-96. PubMed ID: 12066227
[TBL] [Abstract][Full Text] [Related]
26. Overview of interleukin-2 inhalation therapy.
Huland E; Heinzer H; Huland H; Yung R
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S104-12. PubMed ID: 10685669
[TBL] [Abstract][Full Text] [Related]
27. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.
Adler A; Stein JA; Kedar E; Naor D; Weiss DW
J Biol Response Mod; 1984 Oct; 3(5):491-500. PubMed ID: 6334137
[TBL] [Abstract][Full Text] [Related]
28. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of low-dose total body irradiation and subcutaneous interleukin-2 in metastatic melanoma.
Safwat A; Schmidt H; Bastholt L; Fode K; Larsen S; Aggerholm N; von der Maase H
Radiother Oncol; 2005 Nov; 77(2):143-7. PubMed ID: 16216360
[TBL] [Abstract][Full Text] [Related]
30. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
31. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
32. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of renal cell carcinoma with granulocyte macrophage colony stimulating factor and very low dose interleukin-2.
Correale P; Marsili S; Sabatino M; Montagnani F; Giorgi G; Francini G
Oncol Rep; 2005 Apr; 13(4):751-6. PubMed ID: 15756453
[TBL] [Abstract][Full Text] [Related]
34. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
35. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
Elias EG; Zapas JL; Beam SL; Brown SD
Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):15-8. PubMed ID: 15934495
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
[TBL] [Abstract][Full Text] [Related]
38. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
Atkins MB; Kunkel L; Sznol M; Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S11-4. PubMed ID: 10685652
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
40. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
